揭示克唑替尼促进巨核细胞生成以缓解骨髓增生异常肿瘤相关血小板减少的影响
骨髓增生异常肿瘤(MDS)相关血小板减少的治疗选择有限。本研究鉴定克唑替尼为巨核细胞成熟诱导剂,通过靶向Aurora激酶而非其经典靶点ALK/ROS1/c-MET,促进MDS小鼠模型和患者来源巨核细胞多倍体化并增强产血小板能力;在临床前模型中,克唑替尼给药显著改善血小板减少。
要点
- 克唑替尼可诱导MDS小鼠模型及患者来源巨核细胞多倍体化,增强产血小板能力。
- 该作用通过靶向Aurora激酶实现,而非其经典靶点ALK/ROS1/c-MET。
- 在临床前模型中,克唑替尼给药显著改善血小板减少。
核心结论
- 克唑替尼是巨核细胞成熟的有效诱导剂,在临床前模型中显著改善MDS相关血小板减少,提示其药物重定位潜力。
研究设计与样本
- 研究使用MDS小鼠模型和MDS患者来源细胞进行体外及临床前模型实验。
主要发现
- 克唑替尼通过靶向Aurora激酶而非ALK/ROS1/c-MET,诱导MDS小鼠模型和患者来源巨核细胞多倍体化,增强产血小板能力。
- 在临床前模型中,克唑替尼给药显著改善血小板减少。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current therapeutic options for myelodysplastic neoplasms (MDS)-associated thrombocytopenia are limited. Megakaryocyte maturation might be an innovative therapeutic strategy because its dysregulation profoundly contributes to MDS pathogenesis. Here, we identified crizotinib, a clinically approved anti-cancer drug for anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer, as a potent inducer of megakaryocyte maturation. We demonstrated that crizotinib effectively induced polyploidization to increase the platelet-producing capacity of megakaryocytes derived from an MDS murine model and MDS patients by targeting Aurora kinases rather than its canonical targets, ALK/ROS1/c-MET. Importantly, crizotinib administration substantially ameliorated thrombocytopenia in our preclinical model. Our findings underscore the remarkable potential of crizotinib for drug repurposing and offer a novel therapeutic strategy for MDS patients with thrombocytopenia facing health-related quality of life concerns.
引用
- Kobayashi H, Komizo Y, Watanabe N, et al. Unraveling the impact of crizotinib to promote megakaryopoiesis for alleviating thrombocytopenia in myelodysplastic neoplasms. Leukemia. 2025. PMID: 40813622. doi:10.1038/s41375-025-02729-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。